Forte Biosciences, Inc.
FBRX
$17.00
$1.338.49%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -75.86M | -69.38M | -51.74M | -42.45M | -43.71M |
| Total Depreciation and Amortization | 70.00K | 64.00K | 55.00K | 48.00K | 43.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.81M | 6.02M | 4.89M | 4.22M | 3.52M |
| Change in Net Operating Assets | 8.64M | 12.41M | 2.37M | -370.00K | 5.72M |
| Cash from Operations | -59.34M | -50.88M | -44.43M | -38.56M | -34.43M |
| Capital Expenditure | -55.00K | -116.00K | -147.00K | -92.00K | -92.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | 36.35M | 394.00K | 394.00K | 394.00K |
| Cash from Investing | -55.00K | 36.23M | 247.00K | 302.00K | 302.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 76.92M | 76.83M | 129.82M | 128.02M | 53.02M |
| Repurchase of Common Stock | -41.00K | -29.00K | -25.00K | -27.00K | -34.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.13M | -7.44M | -8.56M | -8.09M | -3.44M |
| Cash from Financing | 71.76M | 69.36M | 121.23M | 119.90M | 49.54M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 12.37M | 54.71M | 77.05M | 81.65M | 15.41M |